Farnesoid X receptor agonist represses cytochrome P450 2D6 expression by upregulating small heterodimer partner

Drug Metabolism and Disposition

Volumn 43, Issue 7, 2015, Pages 1002-1007

  Pan, Xian ^a   Lee, Yoon Kwang ^b   Jeong, Hyunyoung ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Northeastern Ohio Medical University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; CYTOCHROME P450 2D6; FARNESOID X RECEPTOR; HETERODIMER; LIVER ENZYME; SMALL HETERODIMER PARTNER; UNCLASSIFIED DRUG; CELL RECEPTOR; CYTOCHROME P450 INHIBITOR; FARNESOID X-ACTIVATED RECEPTOR; ISOXAZOLE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYP2D6 GENE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME MODIFICATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRANSGENIC MOUSE; VALIDATION STUDY; AGONISTS; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; KNOCKOUT MOUSE; METABOLISM;

MUS; MUS MUSCULUS;

ANIMALS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEK293 CELLS; HEPATOCYTES; HUMANS; ISOXAZOLES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION, GENETIC;

EID: 84940195659     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.064758     Document Type: Article

References (38)

1. Akwabi-Ameyaw A., Bass JY, Caldwell R.D., Caravella JA, Chen L, Creech KL, Deaton D.N., Jones SA, Kaldor I, and Liu Y, et al. (2008) Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg Med Chem Lett 18: 4339-4343.
2. Bass JY, Caravella JA, Chen L, Creech K.L., Deaton DN, Madauss KP, Marr HB, McFadyen R.B., Miller AB, and Mills WY, et al. (2011) Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene. Bioorg Med Chem Lett 21: 1206-1213.
3. Benoit G, Cooney A, Giguere V., Ingraham H, Lazar M, Muscat G., Perlmann T, Renaud JP, Schwabe J, and Sladek F, et al. (2006) International Union of Pharmacology. LXVI. Orphan nuclear receptors. Pharmacol Rev 58:798-836.
4. Bertilsson L, Dahl ML, Dalén P, and Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111-122.
5. Cairns W, Smith CA, McLaren A.W., and Wolf CR (1996) Characterization of the human cyto-chrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family. J Biol Chem 271:25269-25276.
6. Carcillo JA, Adedoyin A, Burckart G.J., Frye RF, Venkataramanan R, Knoll C, Thummel K., Roskos L, Wilson JW, and Sereika S, et al. (2003) Coordinated intrahepatic and extrahepatic regulation of cytochrome p4502D6 in healthy subjects and in patients after liver transplantation. Clin Pharmacol Ther 73:456-467.
7. Corchero J, Granvil CP, Akiyama T.E., Hayhurst GP, Pimprale S, Feigenbaum L, Idle J.R., and Gonzalez FJ (2001) The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60: 1260-1267.
8. Dahl ML, Johansson I, Palmertz M.P., Ingelman-Sundberg M, and Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51:12-17.
9. Ellis E, Axelson M, Abrahamsson A., Eggertsen G, Thörne A, Nowak G., Ericzon BG, Björkhem I, and Einarsson C (2003) Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology 38:930-938.
10. Felmlee MA, Lon HK, Gonzalez F.J., and Yu AM (2008) Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 36: 435-441.
11. Gaedigk A, Simon SD, Pearce R.E., Bradford LD, Kennedy MJ, and Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phe-notype. Clin Pharmacol Ther 83:234-242.
12. Goodwin B, Jones SA, Price R.R., Watson MA, McKee DD, Moore LB, Galardi C, Wilson J.G., Lewis MC, and Roth ME, et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517-526.
13. Hou ZY, Pickle LW, Meyer P.S., and Woosley RL (1991) Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 49:410-419.
14. Inoue Y, Yu AM, Yim S.H., Ma X., Krausz KW, Inoue J, Xiang CC, Brownstein M.J., Eggertsen G., and Björkhem I, et al. (2006) Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J Lipid Res 47:215-227.
15. Koh KH, Pan X, Shen H.W., Arnold SL, Yu AM, Gonzalez FJ, Isoherranen N, and Jeong H (2014a) Altered expression of small heterodimer partner governs cytochrome P450 (CYP) 2D6 induction during pregnancy in CYP2D6-humanized mice. J Biol Chem 289:3105-3113.
16. Koh KH, Pan X, Zhang W., McLachlan A, Urrutia R, and Jeong H (2014b) Krüppel-like factor 9 promotes hepatic cytochrome P450 2D6 expression during pregnancy in CYP2D6-humanized mice. Mol Pharmacol 86:727-735.
17. Li G, Thomas AM, Hart S.N., Zhong X., Wu D, and Guo GL (2010) Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small hetero-dimer partner. Mol Endocrinol 24:1404-1412.
18. Li T and Chiang JY (2014) Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 66:948-983.
19. Liu Y, Binz J, Numerick M.J., Dennis S., Luo G, Desai B, MacKenzie K.I., Mansfield TA, Kliewer SA, and Goodwin B, et al. (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112:1678-1687.
20. Maloney PR, Parks DJ, Haffner C.D., Fivush AM, Chandra G, Plunket KD, Creech K.L., Moore LB, Wilson JG, and Lewis MC, et al. (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43:2971-2974.
21. Miao J, Fang S, Lee J., Comstock C, Knudsen KE, and Kemper JK (2009) Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Mol Cell Biol 29:6170-6181.
22. Moschetta A, Bookout AL, and Mangelsdorf DJ (2004) Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 10:1352-1358.
23. Nedumaran B, Hong S, Xie Y.B., Kim YH, Seo WY, Lee MW, Lee C.H., Koo SH, and Choi HS (2009) DAX-1 acts as a novel corepressor of orphan nuclear receptor HNF4alpha and negatively regulates gluconeogenic enzyme gene expression. J Biol Chem 284:27511-27523.
24. Nishimaki-Mogami T., Une M, Fujino T., Sato Y, Tamehiro N, Kawahara Y., Shudo K, and Inoue K (2004) Identification of intermediates in the bile acid synthetic pathway as ligands for the farnesoid X receptor. J Lipid Res 45:1538-1545.
25. Park YJ, Kim SC, Kim J, Anakk S., Lee JM, Tseng HT, Yechoor V, Park J., Choi JS, and Jang HC, et al. (2011) Dissociation of diabetes and obesity in mice lacking orphan nuclear receptor small heterodimer partner. J Lipid Res 52:2234-2244.
26. Parks DJ, Blanchard SG, Bledsoe R.K., Chandra G., Consler TG, Kliewer SA, Stimmel JB, Willson T.M., Zavacki AM, and Moore DD, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365-1368.
27. Pellicciari R, Costantino G, and Fiorucci S (2005) Farnesoid X receptor: from structure to potential clinical applications. J Med Chem 48:5383-5403.
28. Picciotto MR and Wickman K (1998) Using knockout and transgenic mice to study neuro-physiology and behavior. Physiol Rev 78:1131-1163.
29. Porez G, Prawitt J, Gross B., and Staels B (2012) Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 53:1723-1737.
30. Sachse C, Brockmöller J, Bauer S., and Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-295.
31. Temesvári M., Kóbori L, Paulik J., Sárváry E, Belic A, and Monostory K (2012) Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther 341:294-305.
32. Thomas C, Pellicciari R, Pruzanski M., Auwerx J, and Schoonjans K (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7:678-693.
33. Venkatakrishnan K and Obach RS (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 33:845-852.
34. Wang L, Lee YK, Bundman D, Han Y., Thevananther S, Kim CS, Chua S.S., Wei P., Heyman RA, and Karin M, et al. (2002) Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2:721-731.
35. Xie YB, Lee OH, Nedumaran B, Seong H.A., Lee KM, Ha H, Lee IK, Yun Y, and Choi HS (2008) SMILE, a new orphan nuclear receptor SHP-interacting protein, regulates SHP-repressed estrogen receptor transactivation. Biochem J 416:463-473.
36. Xie YB, Nedumaran B, and Choi HS (2009) Molecular characterization of SMILE as a novel corepressor of nuclear receptors. Nucleic Acids Res 37:4100-4115.
37. Zanger UM, Fischer J, Raimundo S., Stüven T, Evert B.O., Schwab M., and Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11:573-585.
38. Zhang Y, Limaye PB, Renaud H.J., and Klaassen CD (2014) Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice. Toxicol Appl Pharmacol 277: 138-145.